Eastern cooperative oncology group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 589-593

  Witte, R S ^a   Elson, P ^a   Bono, B ^a   Knop, R ^a   Richardson, R R ^a   Dreicer, R ^a   Loehrer, P J ^a  

^a GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; MESNA; METHOTREXATE; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; URINARY TRACT CARCINOMA;

EID: 0031017367     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.589     Document Type: Article

References (24)

1. Yagoda A: Chemotherapy for advanced urothelial cancer. Semin Urol 1:60-74, 1983
2. Sternberg CN, Yagoda A, Scher HI, et al.: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64:2448-2458, 1989
3. Harker WG, Meyers FJ, Freiha FS, et al.: Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: A Northern California Oncology Group study. J Clin Oncol 3:1463-1470, 1985
4. Loehrer PJ, Einhorn LH, Elson PJ, et al.: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group trial. J Clin Oncol 10:1066-1073, 1992
5. Kolvin M: The comparative pharmacology of cyclophosphamide and IFX. Semin Oncol 9:2-7, 1982 (suppl)
6. Scheulen ME, Niederlen, Bremer K, et al.: Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: Results of a clinical phase II trial with 151 patients. Cancer Treat Rev 10:93-101, 1983 (suppl)
7. Scheef W, Clein HO, Prock N, et al.: Controlled clinical studies with an antidote against urotoxicity of oxazaphosphorine: Preliminary results. Cancer Treat Rep 63:501-505, 1979
8. Ryan DH, Bickers JN, Vial RH, et al.: Doxorubicin and ifosfamide combination chemotherapy in previously treated acute leukemia in adults: A Southwest Oncology Group pilot study. Cancer Treat Rep 64:869-872, 1980
9. Cabinilla F, Rodriquez V, Bodey GP: Ifosfamide, methotrexate, vincristine (IMV) combination chemotherapy as second line treatment for patients with malignant lymphoma. Cancer Treat Rep 64:933-937, 1980
10. Morgan RL, Posey LE, Rainey J, et al.: Ifosfamide: A weekly dose fractionated schedule in bronchogenic carcinoma. Cancer Treat Rep 65:693-695, 1981
11. Costanzi JJ, Gagliano R, Loukas D, et al.: Ifosfamide in the treatment of recurrent or disseminated lung cancer: A phase II study of two dose schedules. Cancer 41:1715-1719, 1978
12. Wolf M, Haveman R, Holle R, et al.: Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: A multicenter German randomized trial. J Clin Oncol 5:1880-1889, 1987
13. Handelsman H, Goldsmith MA, Slavik M: Ifosfamide (NSC 109724). Bethesda, MD, Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, 1974
14. Loehrer PJ Sr, Lauer R, Roth BJ, et al.: Salvage therapy for recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 109:540-546, 1988
15. Oken MM, Creech RH, Tormey DC, et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
17. Gad-el-Mawla N, Ziegler J, Hamza R, et al.: Phase II chemotherapy trials of 5-FU, cyclophosphamide, ifosfamide, and vincristine in carcinoma of the bilharzial bladder. Cancer Treat Rep 68:419-420, 1984
18. Soloway MS, Einstein A, Corder MP, et al.: A comparison of cisplatin and cyclophosphamide in advanced urothelial carcinoma: A National Bladder Cancer Cooperative Group A Study. Cancer 52:767-772, 1983
19. Khandekar JD, Elson PJ, DeWys WD, et al.: Comparative activity and toxicity of cis-diamminedichloropaltinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinoma of the urinary tract. J Clin Oncol 3:539-545, 1985
20. Troner M, Birch R, Omura GA, et al.: Phase II comparison of cisplatin alone versus cisplatin, doxorubicin, and cyclophosphamide in the treatment of bladder (urothelial) cancer: A Southeastern Cancer Study Group trial. J Urol 137:660-662, 1987
21. Antman K, Ryan L, Elias A, et al.: Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 7:126-131, 1989
22. Elias A, Eder JP, Shea T, et al.: High-dose ifosfamide with mesna uroprotection: A phase I study. J Clin Oncol 8:170-178, 1990
23. Pratt CB, Goren MP, Meyer WH, et al.: Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors. J Clin Oncol 8:1399-1401, 1990
24. Einhorn LH, Roth BJ, Ansari R, et al.: Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 12:2271-2276, 1994